LT3099306T - Steroidinis junginys, skirtas panaudoti kepenų encefalopatijos gydymui - Google Patents

Steroidinis junginys, skirtas panaudoti kepenų encefalopatijos gydymui

Info

Publication number
LT3099306T
LT3099306T LTEP15705691.2T LT15705691T LT3099306T LT 3099306 T LT3099306 T LT 3099306T LT 15705691 T LT15705691 T LT 15705691T LT 3099306 T LT3099306 T LT 3099306T
Authority
LT
Lithuania
Prior art keywords
treatment
hepatic encephalopathy
steroid compound
steroid
compound
Prior art date
Application number
LTEP15705691.2T
Other languages
English (en)
Inventor
Magnus DOVERSKOG
Hanns MÖHLER
Vicente FELIPO
Torbjörn BÄCKSTRÖM
Original Assignee
Umecrine Cognition Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Cognition Ab filed Critical Umecrine Cognition Ab
Publication of LT3099306T publication Critical patent/LT3099306T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP15705691.2T 2014-01-29 2015-01-14 Steroidinis junginys, skirtas panaudoti kepenų encefalopatijos gydymui LT3099306T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1450089 2014-01-29
PCT/GB2015/050060 WO2015114308A1 (en) 2014-01-29 2015-01-14 Steroid compound for use in the treatment of hepatic encephalopathy

Publications (1)

Publication Number Publication Date
LT3099306T true LT3099306T (lt) 2019-03-12

Family

ID=52544513

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15705691.2T LT3099306T (lt) 2014-01-29 2015-01-14 Steroidinis junginys, skirtas panaudoti kepenų encefalopatijos gydymui

Country Status (24)

Country Link
US (3) US20160339040A1 (lt)
EP (1) EP3099306B1 (lt)
JP (1) JP6543633B2 (lt)
KR (1) KR102324667B1 (lt)
CN (2) CN106163528A (lt)
AU (1) AU2015212606B2 (lt)
BR (1) BR112016017620A2 (lt)
CA (1) CA2935015C (lt)
CY (1) CY1121464T1 (lt)
DK (1) DK3099306T3 (lt)
ES (1) ES2714563T3 (lt)
HR (1) HRP20190251T1 (lt)
HU (1) HUE042242T2 (lt)
IL (1) IL246496B (lt)
LT (1) LT3099306T (lt)
ME (1) ME03351B (lt)
MX (1) MX2016008851A (lt)
PL (1) PL3099306T3 (lt)
PT (1) PT3099306T (lt)
RS (1) RS58375B1 (lt)
RU (1) RU2684616C2 (lt)
SI (1) SI3099306T1 (lt)
TR (1) TR201901687T4 (lt)
WO (1) WO2015114308A1 (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163528A (zh) 2014-01-29 2016-11-23 梅克芳识别有限公司 用于治疗肝脑病的甾族化合物
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
JP7203438B2 (ja) 2017-09-12 2023-01-13 イーティーエイチ・チューリッヒ 体液中アンモニア定量用の膜貫通pH勾配ポリマーソーム
BR112020010519A2 (pt) 2017-11-27 2020-10-20 Umecrine Cognition Ab formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
US20230134958A1 (en) * 2021-10-29 2023-05-04 Umecrine Cognition Ab New medical treatment
EP4389129A1 (en) 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713061A (en) 1951-04-06 1955-07-12 Schering Ag 3-methyl androstanes
FR1463755A (fr) 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3173932A (en) 1962-11-02 1965-03-16 American Cyanamid Co 15-substituted estra-1, 3, 5(10)-trienes
FR2685332A1 (fr) 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.
EP0701444B1 (en) 1993-05-24 2010-04-07 Purdue Pharma Ltd. Methods and compositions for inducing sleep
JP3877961B2 (ja) 1998-03-11 2007-02-07 ベクストルム,トルビエーン Cns疾患の治療におけるエピアロプレグナノロン
US6593321B2 (en) 2001-06-11 2003-07-15 Southwest Foundation For Biomedical Research 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
SI2319581T1 (sl) 2004-11-26 2015-10-30 Ucl Business Plc Pripravki, ki obsegajo ornitin in fenilacetat ali fenilbutirat za zdravljenje hepatične encefalopatije
WO2007103162A2 (en) * 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
US8580983B2 (en) * 2006-11-21 2013-11-12 Umecrine Ab Steroids having increased water solubility and resistance against metabolism, and methods for their production
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
SI3628319T1 (sl) * 2008-10-02 2024-04-30 Salix Pharmaceuticals, Ltd. Zdravljenje jetrne encefalopatije z rifaksiminom
BRPI1012956A8 (pt) 2009-06-08 2021-11-03 Ocera Therapeutics Inc Usos da l-ornitina e de pelo menos um de fenilacetato e fenilbutirato
EP3019074B1 (en) 2013-09-30 2018-08-29 Horizon Therapeutics, LLC Diagnosing, grading, monitoring, and treating hepatic encephalopathy
CN106163528A (zh) 2014-01-29 2016-11-23 梅克芳识别有限公司 用于治疗肝脑病的甾族化合物

Also Published As

Publication number Publication date
US20160339040A1 (en) 2016-11-24
WO2015114308A1 (en) 2015-08-06
ES2714563T3 (es) 2019-05-29
JP6543633B2 (ja) 2019-07-10
CY1121464T1 (el) 2020-05-29
JP2017507113A (ja) 2017-03-16
RU2016127558A3 (lt) 2018-09-27
PT3099306T (pt) 2019-03-21
DK3099306T3 (en) 2019-03-18
US10342804B2 (en) 2019-07-09
BR112016017620A2 (pt) 2017-08-08
AU2015212606A1 (en) 2016-07-14
RU2016127558A (ru) 2018-03-05
US20180015103A1 (en) 2018-01-18
PL3099306T3 (pl) 2019-06-28
SI3099306T1 (sl) 2019-03-29
TR201901687T4 (tr) 2019-02-21
MX2016008851A (es) 2017-03-23
CN106163528A (zh) 2016-11-23
KR20160105922A (ko) 2016-09-07
WO2015114308A8 (en) 2016-07-21
CN113185566A (zh) 2021-07-30
RU2684616C2 (ru) 2019-04-10
AU2015212606B2 (en) 2019-11-21
HUE042242T2 (hu) 2019-06-28
IL246496B (en) 2019-09-26
CA2935015A1 (en) 2015-08-06
RS58375B1 (sr) 2019-03-29
EP3099306B1 (en) 2018-12-12
NZ721622A (en) 2020-11-27
ME03351B (me) 2019-10-20
US20170056416A1 (en) 2017-03-02
EP3099306A1 (en) 2016-12-07
HRP20190251T1 (hr) 2019-04-05
US9801894B2 (en) 2017-10-31
IL246496A0 (en) 2016-08-31
KR102324667B1 (ko) 2021-11-10
CA2935015C (en) 2022-05-31

Similar Documents

Publication Publication Date Title
IL250685A0 (en) Medicinal substance induces cytotoxicity
HRP20190251T1 (hr) Steroidni spoj za upotrebu za liječenje jetrene encefalopatije
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
GB201400442D0 (en) Compositions for use in the treatment of ulcerative colitis
HK1244485A1 (zh) 用於治療神經母細胞瘤的組合物
LT3456330T (lt) Korteksolono 17 alfa-valeratas, skirtas naudoti navikų gydymui
IL251904B (en) Epilimod for use in the treatment of melanoma
ZA201608784B (en) Fused triterpene compounds and uses thereof
IL246855A0 (en) Materials for use in the treatment of retinitis
HK1252811A1 (zh) 用於去勢治療相關症狀之治療的化合物
IL249075B (en) agent for fluoroalkylation
HK1221883A1 (zh) 搓澡巾
SG11201703577RA (en) Bathroom unit
HK1226296A1 (zh) 用於產生視黃酸的試劑
PL3129398T3 (pl) Nowe środki medyczne i ich zastosowanie
HK1217430A1 (zh) 表面處理劑
GB201418541D0 (en) Materials for use with general hyperthermia treatment
PT3370727T (pt) Derivados da pregnenolona substituídos em c3 não bioconvertíveis para utilização no tratamento de distúrbios de toxicodependência
ZA201408464B (en) Composition for the use in treatment of asthma
GB201404124D0 (en) The theory of european monetary